Your browser doesn't support javascript.
loading
Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency.
Marin-Bejar, Oskar; Romero-Moya, Damia; Rodriguez-Ubreva, Javier; Distefano, Maximiliano; Lessi, Francesca; Aretini, Paolo; Liquori, Alessandro; Castaño, Julio; Kozyra, Emilia; Kotmayer, Lili; Bueno, Clara; Cervera, José; Rodriguez-Gallego, José Carlos; Nomdedeu, Josep F; Murillo-Sanjuán, Laura; De Heredia, Cristina Díaz; Pérez-Martinez, Antonio; López-Cadenas, Félix; Martínez-Laperche, Carolina; Dorado-Herrero, Nieves; Marco, Francisco M; Prósper, Felipe; Menendez, Pablo; Valcárcel, David; Ballestar, Esteban; Bödör, Csaba; Bigas, Anna; Catalá, Albert; Wlodarski, Marcin W; Giorgetti, Alessandra.
Affiliation
  • Marin-Bejar O; Regenerative Medicine Program, Bellvitge Institute for Biomedical Research (IDIBELL) and Program for Clinical Translation of Regenerative Medicine in Catalonia (P-CMRC), Barcelona. omarin@idibell.cat.
  • Romero-Moya D; Regenerative Medicine Program, Bellvitge Institute for Biomedical Research (IDIBELL) and Program for Clinical Translation of Regenerative Medicine in Catalonia (P-CMRC), Barcelona.
  • Rodriguez-Ubreva J; Epigenetics and Immune Disease Group, Josep Carreras Research Institute (IJC), Barcelona.
  • Distefano M; Department of Hematology and Oncology, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona.
  • Lessi F; Fondazione Pisana Per la Scienza ONLUS (FPS), San Giuliano Terme.
  • Aretini P; Fondazione Pisana Per la Scienza ONLUS (FPS), San Giuliano Terme.
  • Liquori A; Hematology Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain; Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Instituto de Salud Carlos III, Madrid.
  • Castaño J; Advanced and Cell Therapy Services. Banc de Sang i Teixits, Barcelona.
  • Kozyra E; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine; Faculty of Biology, University of Freiburg, Freiburg.
  • Kotmayer L; HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University. Budapest, Hungary.
  • Bueno C; Josep Carreras Leukaemia Research Institute. Department of Biomedicine. School of Medicine, University of Barcelona, Barcelona.
  • Cervera J; Hematology Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain; Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain; Genetics Unit, Hospital Universitario y Politécnico La Fe, Valencia.
  • Rodriguez-Gallego JC; Department of Immunology, University Hospital of Gran Canaria Dr. Negrin, Canarian Health System, Las Palmas de Gran Canaria, Spain; Department of Clinical Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain; Department of Medical and Surgical Sciences, School of Medicin
  • Nomdedeu JF; Servei d'Hematologia Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, IIB Sant Pau/Josep Carreras Leukaemia Research Institute (IJC), Barcelona.
  • Murillo-Sanjuán L; Pediatric Hematology and Oncology Division, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Barcelona.
  • De Heredia CD; Pediatric Hematology and Oncology Division, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Barcelona.
  • Pérez-Martinez A; Pediatric Department, Universidad Autonoma de Madrid, Madrid, Spain; Hospital La Paz Institute for Health Research, Madrid, Spain; Pediatric Hemato-Oncology Department, University Hospital La Paz, Madrid.
  • López-Cadenas F; Servicio de Hematología Hospital Clínico Universitario de Salamanca, salamanca, Spain; Instituto Biosanitario de Salamanca (IBSAL). Salamanca.
  • Martínez-Laperche C; Servicio de Hematología, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid.
  • Dorado-Herrero N; Servicio de Hematología, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid.
  • Marco FM; Immunology Department, Dr. Balmis General University Hospital; Institute for Health and Biomedical Research (ISABIAL), Alicante.
  • Prósper F; Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain; Area de Hemato-Oncología, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain; Servicio de Hematologia, CCUN, Clínica Universidad de Nava
  • Menendez P; Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain; Josep Carreras Leukaemia Research Institute. Department of Biomedicine. School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terapias Avanzadas (TERAV) - Institut
  • Valcárcel D; Servei d'Hematologia, Vall d'Hebron Hospital Universitari; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO); Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona.
  • Ballestar E; Epigenetics and Immune Disease Group, Josep Carreras Research Institute (IJC), Barcelona, Spain; Epigenetics in Inflammatory and Metabolic Diseases Laboratory, Health Science Center (HSC), East China Normal University (ECNU), Shanghai.
  • Bödör C; HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University. Budapest, Hungary.
  • Bigas A; Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain; Programa de Investigación en Cáncer, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Josep Carreras Leukaemia Research Institute (IJC), Barcelona.
  • Catalá A; Department of Hematology and Oncology, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid.
  • Wlodarski MW; Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN.
  • Giorgetti A; Regenerative Medicine Program, Bellvitge Institute for Biomedical Research (IDIBELL) and Program for Clinical Translation of Regenerative Medicine in Catalonia (P-CMRC), Barcelona, Spain; Fondazione Pisana Per la Scienza ONLUS (FPS), San Giuliano Terme, Italy; Department of Pathology and Experimenta
Haematologica ; 108(9): 2551-2557, 2023 09 01.
Article in En | MEDLINE | ID: mdl-36815365
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: DNA Methylation / GATA2 Deficiency / Epigenome Limits: Humans Language: En Journal: Haematologica Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: DNA Methylation / GATA2 Deficiency / Epigenome Limits: Humans Language: En Journal: Haematologica Year: 2023 Type: Article